- Home
- ICCH vs CASI Comparison
ICCH vs CASI Comparison
Compare ICCH & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCH
- CASI
- Stock Information
- Founded
- ICCH 1950
- CASI 1991
- Country
- ICCH United States
- CASI China
- Employees
- ICCH N/A
- CASI N/A
- Industry
- ICCH Property-Casualty Insurers
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- ICCH Finance
- CASI Health Care
- Exchange
- ICCH Nasdaq
- CASI Nasdaq
- Market Cap
- ICCH 68.8M
- CASI 58.8M
- IPO Year
- ICCH 2017
- CASI 1996
- Fundamental
- Price
- ICCH $23.29
- CASI $2.52
- Analyst Decision
- ICCH
- CASI Strong Buy
- Analyst Count
- ICCH 0
- CASI 1
- Target Price
- ICCH N/A
- CASI $6.00
- AVG Volume (30 Days)
- ICCH 5.7K
- CASI 42.2K
- Earning Date
- ICCH 03-03-2025
- CASI 11-15-2024
- Dividend Yield
- ICCH N/A
- CASI N/A
- EPS Growth
- ICCH 42.86
- CASI N/A
- EPS
- ICCH 2.16
- CASI N/A
- Revenue
- ICCH $92,541,259.00
- CASI $22,055,000.00
- Revenue This Year
- ICCH N/A
- CASI N/A
- Revenue Next Year
- ICCH N/A
- CASI $134.79
- P/E Ratio
- ICCH $10.77
- CASI N/A
- Revenue Growth
- ICCH 14.09
- CASI N/A
- 52 Week Low
- ICCH $14.78
- CASI $2.05
- 52 Week High
- ICCH $23.96
- CASI $8.19
- Technical
- Relative Strength Index (RSI)
- ICCH 48.99
- CASI 38.24
- Support Level
- ICCH $23.23
- CASI $2.44
- Resistance Level
- ICCH $23.47
- CASI $2.86
- Average True Range (ATR)
- ICCH 0.05
- CASI 0.27
- MACD
- ICCH -0.02
- CASI 0.04
- Stochastic Oscillator
- ICCH 25.00
- CASI 18.82
About ICCH ICC Holdings Inc.
ICC Holdings Inc is a specialty insurance carrier underwriting commercial multi-peril, liquor liability, worker's compensation, and umbrella liability coverages for the food and beverage industry. The company markets its products through a network of independent agents in Colorado, Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri, Pennsylvania, Ohio, and Wisconsin.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.